Du L - Search Results

1

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is.

Du L, Zhang Y, Wang P, Li Z, Zhao Y. Du L, et al. Front Cardiovasc Med. 2022 Oct 18;9:1034095. doi: 10.3389/fcvm.2022.1034095. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36330012 Free PMC article. No abstract available.

2

GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?

Du L, Zhang Y, Wang P, Li Z, Zhao Y, Yuan J. Du L, et al. Int J Cardiol. 2022 Nov 1;366:31. doi: 10.1016/j.ijcard.2022.07.015. Epub 2022 Jul 14. Int J Cardiol. 2022. PMID: 35839931 No abstract available.

3

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality.

Du L, Qin J, Wang D, Zhao Y, Xu N, Wu C. Du L, et al. Front Cardiovasc Med. 2022 Aug 4;9:987025. doi: 10.3389/fcvm.2022.987025. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35990975 Free PMC article. No abstract available.

4

Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke.

Du L, Wang P, Chen H, Zhang Y, Ma J. Du L, et al. Can J Cardiol. 2023 Jan;39(1):89. doi: 10.1016/j.cjca.2022.08.223. Epub 2022 Aug 23. Can J Cardiol. 2023. PMID: 36007809 No abstract available.

5

Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?

Du L, Li Z, Lan P, Huang H, Cheng W, Xia J. Du L, et al. Eur J Clin Pharmacol. 2022 Oct;78(10):1703-1704. doi: 10.1007/s00228-022-03377-0. Epub 2022 Aug 25. Eur J Clin Pharmacol. 2022. PMID: 36008491 No abstract available.

6

Correction to: Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?

Du L, Li Z, Lan P, Huang H, Cheng W, Xia J. Du L, et al. Eur J Clin Pharmacol. 2022 Oct;78(10):1705. doi: 10.1007/s00228-022-03392-1. Eur J Clin Pharmacol. 2022. PMID: 36109392 No abstract available.

7

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status.

Du L, Li Z, Lan P, Huang H, Cheng W. Du L, et al. Front Cardiovasc Med. 2022 Sep 6;9:1011535. doi: 10.3389/fcvm.2022.1011535. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36148068 Free PMC article. No abstract available.

8

Among patients with MINOCA women versus men have the increased risks of MACE and stroke?

Du L, Wang P, Chen H, Zhang Y, Ma J, Wen G. Du L, et al. Int J Cardiol. 2023 Jan 15;371:82. doi: 10.1016/j.ijcard.2022.09.040. Epub 2022 Sep 21. Int J Cardiol. 2023. PMID: 36152682 No abstract available.

9

Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?

Du L, Qin J, Zhang Y. Du L, et al. Diabetes Obes Metab. 2023 Feb;25(2):628-629. doi: 10.1111/dom.14878. Epub 2022 Oct 14. Diabetes Obes Metab. 2023. PMID: 36181390 No abstract available.

10

GLP1RAs vs SGLT2is were associated with lower risk of major adverse limb events and similar risks of heart failure hospitalisation and stroke?

Du L, Wang P, Chen H, Zhang Y, Ma J. Du L, et al. Diabetologia. 2023 Mar;66(3):605-606. doi: 10.1007/s00125-022-05835-x. Epub 2022 Nov 18. Diabetologia. 2023. PMID: 36399206 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,042 results

Search Page

Filters